Gianluca Masi
AuthID: R-00K-CD9
1
TITLE: Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population Full Text
AUTHORS: Casadei Gardini, Andrea; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...More
PUBLISHED: 2023, SOURCE: EUROPEAN JOURNAL OF CANCER, VOLUME: 180
AUTHORS: Casadei Gardini, Andrea; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...More
PUBLISHED: 2023, SOURCE: EUROPEAN JOURNAL OF CANCER, VOLUME: 180
INDEXED IN: Scopus WOS
2
TITLE: Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? Full Text
AUTHORS: Rimini, Margherita; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Piscaglia, Fabio; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: TARGETED ONCOLOGY
AUTHORS: Rimini, Margherita; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Piscaglia, Fabio; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: TARGETED ONCOLOGY
INDEXED IN: Scopus WOS
3
TITLE: Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab Full Text
AUTHORS: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa Ramos, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Stefanini, Bernardo; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: ONCOLOGY, VOLUME: 101, ISSUE: 5
AUTHORS: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa Ramos, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Stefanini, Bernardo; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: ONCOLOGY, VOLUME: 101, ISSUE: 5
INDEXED IN: Scopus WOS
4
TITLE: Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index
AUTHORS: Persano, M; Rimini, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Yoo, C; Lonardi, S; Pressiani, T; Piscaglia, F; Kumada, T; Rimassa, L; Scartozzi, M; Cascinu, S; Casadei Gardini, A; ...More
PUBLISHED: 2023, SOURCE: ANTICANCER RESEARCH, VOLUME: 43, ISSUE: 4
AUTHORS: Persano, M; Rimini, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Yoo, C; Lonardi, S; Pressiani, T; Piscaglia, F; Kumada, T; Rimassa, L; Scartozzi, M; Cascinu, S; Casadei Gardini, A; ...More
PUBLISHED: 2023, SOURCE: ANTICANCER RESEARCH, VOLUME: 43, ISSUE: 4
INDEXED IN: Scopus WOS
5
TITLE: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients Full Text
AUTHORS: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: EUROPEAN JOURNAL OF CANCER, VOLUME: 189
AUTHORS: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: EUROPEAN JOURNAL OF CANCER, VOLUME: 189
INDEXED IN: Scopus WOS
6
TITLE: α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma Full Text
AUTHORS: Rossari, Federico; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Yoo, Changhoon; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Bergamo, Francesca; Amadeo, Elisabeth; Vitiello, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: INTERNATIONAL JOURNAL OF CANCER
AUTHORS: Rossari, Federico; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Yoo, Changhoon; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Bergamo, Francesca; Amadeo, Elisabeth; Vitiello, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...More
PUBLISHED: 2023, SOURCE: INTERNATIONAL JOURNAL OF CANCER
INDEXED IN: Scopus WOS
7
TITLE: Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.
AUTHORS: Rimini, Margherita; Casadei Gardini, Andrea; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Scartozzi, Mario; Burgio, Valentina; Cascinu, Stefano; Cucchetti, Alessandro;
PUBLISHED: 2023, SOURCE: Genitourinary Cancers Symposium in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 41
AUTHORS: Rimini, Margherita; Casadei Gardini, Andrea; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Scartozzi, Mario; Burgio, Valentina; Cascinu, Stefano; Cucchetti, Alessandro;
PUBLISHED: 2023, SOURCE: Genitourinary Cancers Symposium in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 41
INDEXED IN: WOS
8
TITLE: Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: WOS
9
TITLE: Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
AUTHORS: Rimini, M.; Amadeo, E.; Vitiello, F.; Foti, S.; Persano, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Piscaglia, F.; Masi, G.; Yoo, C.; Lonardi, S.; Rossari, F.; Camera, S.; Gardini, A. Casadei; Presa, J.;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
AUTHORS: Rimini, M.; Amadeo, E.; Vitiello, F.; Foti, S.; Persano, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Piscaglia, F.; Masi, G.; Yoo, C.; Lonardi, S.; Rossari, F.; Camera, S.; Gardini, A. Casadei; Presa, J.;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: WOS
10
TITLE: Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: WOS